IP Group is a London-listed science investor and the biggest shareholder in Oxford Nanopore.
The financing round was co-led by Tencent and Flerie Invest to support Phase 1b clinical studies and pipeline expansion.
"This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome's therapeutic potential and Microbiotica's unique capabilities."
The round was led by IP Group to support the development of low-carbon heating and cooling systems.
"Heating and cooling accounts for 38% of the UK’s CO₂ emissions,"
HydrogenOne Capital Growth led the Series B round with support from IP Group, Parkwalk Advisors, BGF, and the UCL Technology Fund.
"Hydrogen, through its green production from electrolysis or its use in fuel cells to provide clean power, is critical for the transition to net zero. Bramble Energy brings a fundamentally different approach to these technologies, unlocking the deployment of hydrogen faster, more flexibly and at scale. We are delighted to contribute substantially to this significant funding round which will take Bramble to the next stage."
The Oxford Science Enterprises-led round will support US expansion and continued domestic growth in healthcare.
"I’m delighted our investors have again demonstrated their belief in the vast potential that Navenio can bring by ensuring ‘right person, right place, right time’. Artificial intelligence is one of many technologies making a real-world impact in the health sector, and this investment enables the company to rapidly spearhead international digital transformation."
Morningside led the Series B financing to support regulatory approvals and market entry for clinical software treatments.
"At ieso, we’re looking to transform global mental health by unlocking the power of clinical data to develop AI-enabled digital therapeutics. Our experience delivering outstanding mental health care within the NHS ideally places us for starting to tackle this challenge. A new generation of clinically-validated digital mental health care products could ultimately improve millions of lives. But we cannot do this alone, and look forward to working with our patients, clinicians, investors, as well as existing and future partners, to better serve those who require mental health support."
